SH PIONEER HLDG1345.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, SH PIONEER HLDG (1345.HK) trades at a P/E of 18.60x, P/B of 2.17x, P/S of 1.84x, and a dividend yield of 5.32%.
Longitudinal percentile comparison: P/E sits at the 75th percentile over the trailing 10Y window (vs. 57th percentile over 3Y); P/B sits at the 45th percentile over the trailing 10Y window (vs. 28th percentile over 3Y); P/S sits at the 84th percentile over the trailing 10Y window (vs. 68th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 57th percentile within its industry and the 70th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.32%, ranking at the 63rd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 30.1 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SH PIONEER HLDG operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1345 · SEHK: 1345 · 1345
Want the full picture on whether SH PIONEER HLDG (1345.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 18.60 | ||||||
| P/B (MRQ) | 2.17 | ||||||
| P/S (TTM) | 1.84 | ||||||
| Dividend Yield | 5.32% | ||||||
| Buyback + Div Yield | 5.32% |